Abegail S. Syparrado
⚠️ Moderate Risk
FEI: 3006993362 • Cebu, Central Visayas • PHILIPPINES
FEI Number
3006993362
Location
Cebu, Central Visayas
Country
PHILIPPINESAddress
140 C.P. Batiller Street,Umapadmandaue, , Cebu, Central Visayas, Philippines
Moderate Risk
FDA Import Risk Assessment
This firm has a moderate history of FDA import refusals. Some attention may be warranted.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
Refusal History
Frequently Asked Questions
What is Abegail S. Syparrado's FDA import refusal history?
Abegail S. Syparrado (FEI: 3006993362) has 2 FDA import refusal record(s) in our database, spanning from 7/11/2008 to 7/11/2008.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Abegail S. Syparrado's FEI number is 3006993362.
What types of violations has Abegail S. Syparrado received?
Abegail S. Syparrado has been cited for 1 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Abegail S. Syparrado come from?
All FDA import refusal data for Abegail S. Syparrado is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.